Wenzel S.E. (1997) Arachidonic acid metabolites: Mediators of inflammation in asthma. Pharmacotherapy 17(1 PART 2).
Devillier P., Bessard G. (1997) Thromboxane A2 and related prostaglandins in airways. Fundam. Clin. Pharmacol. 11(1):2-18.
Obata T., Yamashita N., Nakagawa T. (1994) Leukotriene and thromboxane antagonists. Clin. Rev. Allergy 12(1):79-93.
Taylor I.K., Ward P.S., O'Shaughnessy K.M. (1991) Thromboxane A2 biosynthesis in acute asthma and after antigen challenge. Am. Rev. Respir. Dis. 143(1):119-125.
O'Byrne P.M., Fuller R.W. (1989) The role of thromboxane A2 in the pathogenesis of airway hyperresponsiveness. Eur. Respir. J. 2(8):782-786.
Hui K.P., Taylor I.K., Taylor G.W. (1991) Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 46(3):184-189.
Westcott J.Y., Johnston K., Batt R.A. (1990) Measurement of peptidoleukotrienes in biological fluids. J. Appl. Physiol. 68(6):2640-2648.
Bisgaard H. (2001) Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 56(SUPPL. 66):7-11.
Leff A.R. (2001) Discovery of leukotrienes and development of antileukotriene agents. Ann. Allergy Asthma Immunol. 86(6 SUPPL. 1):4-8.
Bisgaard H. (2000) Role of leukotrienes in asthma pathophysiology. Pediatr. Pulmonol. 30(2):166-176.
Barnes N.C., Smith L.J. (1999) Biochemistry and physiology of the leukotrienes. Clin. Rev. Allergy Immunol. 17(1-2):27-42.
Sorkness C.A. (2001) Leukotriene receptor antagonists in the treatment of asthma. Pharmacotherapy 21(3 PART 2).
Nathan R.A., Kemp J.P. (2001) Efficacy of antileukotriene agents in asthma management. Ann. Allergy Asthma Immunol. 86(6 SUPPL. 1):9-17.
Pawlowski N.A., Kaplan G., Hamill A.L. (1983) Arachidonic acid metabolism by human monocytes. Studies with plateletdepleted cultures. J. Exp. Med. 158(2):393-412.
Beasley R.C., Featherstone R.L., Church M.K. (1989) Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J. Appl. Physiol. 66(4):1685-1693.
Hamberg M., Svensson J., Samuelsson B. (1975) Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72(8):2994-2998.
Ellis E.F., Oelz O., Roberts L.J. (1976) Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science 193(4258):1135-1137.
Suzuki N., Hishinuma T., Abe F. (2000) Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients. Prostaglandins Lipid Mediat. 62(4):395-403.
Tanaka H., Igarashi T., Saitoh T. (1999) Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients?. Respir. Med. 93(12):891-897.
Svensson J., Strandberg K., Tuvemo T. (1977) Thromboxane A2: Effects on airway and vascular smooth muscle. Prostaglandins 14:425-436.
Minoguchi K., Adachi M., Tokunaga H. (1993) Change in responsiveness of airway and beta-adrenoceptor in guinea pigs. Arerugi 42(4):556-563.
Chung K.F., Aizawa H., Leikauf G.D. (1986) Airway hyperresponsiveness induced by platelet-activating factor: Role of thromboxane generation. J. Pharmacol. Exp. Ther. 236(3):580-584.
Muccitelli R.M., Osborn R.R., Weichman B.M. (1983) Effect of inhibition of thromboxane production on the leukotriene D4-mediated bronchoconstriction in the guinea pig. Prostaglandins 26(2):197-206.
Kurosawa M., Tsukagoshi H. (1993) Inhibitory effect of a thromboxane A2 synthetase inhibitor OKY-046 on bronchial hyperresponsiveness to histamine, but not on airway wall thickening, induced by intravenous administration of leukotriene C4 in guinea-pigs. Pulm. Pharmacol. 6(4):247-253.
O'Byrne P.M., Leikauf G.D., Aizawa H. (1985) Leukotriene B4 induces airway hyperresponsiveness in dogs. J. Appl. Physiol. 59(6):1941-1946.
Ueno A., Tanaka K., Katori M. (1982) Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs. Prostaglandins 23(6):865-880.
Ninomiya H., Yu X.Y., Hasegawa S. (1992) Endothelin-1 induces stimulation of prostaglandin synthesis in cells obtained from canine airways by bronchoalveolar lavage. Prostaglandins 43(5):401-411.
Held H.D., Uhlig S. (2000) Mechanisms of endotoxin-induced airway and pulmonary vascular hyperreactivity in mice. Am. J. Respir. Crit. Care Med. 162(4 PART 1):1547-1552.
Aizawa H., Chung K.F., Leikauf G.D. (1985) Significance of thromboxane generation in ozone-induced airway hyperresponsiveness in dogs. J. Appl. Physiol. 59(6):1918-1923.
Kurosawa M. (1995) Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. Clin. Ther. 17(1):2-11.
Stenton S.C., Young C.A., Harris A. (1992) The effect of GR32191 on airway responsiveness in asthma. Pulm. Pharmacol. 5(3):199-202.
Fujimura M., Sasaki F., Nakatsumi Y. (1986) Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 41(12):955-959.
Fujimura M., Nishioka S., Kumabashiri I. (1990) Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects. Chest 98(2):276-279.
Fujimura M., Sakamoto S., Saito M. (1991) Effect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma. J. Allergy Clin. Immunol. 87(1 PART 1):23-27.
Jones G.L., Saroea H.G., Watson R.M. (1992) Effect of an inhaled thromboxane mimetic (U46619) on airway function in human subjects. Am. Rev. Respir. Dis. 145(6):1270-1274.
Chung K.F., Evans T.W., Graf P.D. (1985) Modulation of cholinergic neurotransmission in canine airways by thromboxane mimetic U46619. Eur. J. Pharmacol. 117(3):373-375.
Munoz N.M., Shioya T., Murphy T.M. (1986) Potentiation of vagal contractile response by thromboxane mimetic U-46619. J. Appl. Physiol. 61(3):1173-1179.
Aizawa H., Takata S., Shigyo M. (1995) Effect of BAY u3405, a thromboxane A2 receptor antagonist, on neuro-effector transmission in canine tracheal tissue. Prostaglandins Leukot. Essent. Fatty Acids 53(3):213-217.
Nakazawa M., Iizuka K., Ujiie A. (1994) Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase. Yakugaku Zasshi. 114(12):911-933.
Fujimura M., Miyake Y., Uotani K. (1988) Secondary release of thromboxane A2 in aerosol leukotriene C4-induced bronchoconstriction in guinea pigs. Prostaglandins 35(3):427-435.
Nambu F., Shiraji T., Motoishi M. (1989) Effect of an oral thromboxane synthetase inhibitor (OKY-046) on antigen-induced bronchoconstriction in guinea pigs. Adv. Prostaglandin Thromboxane Leukot. Res. 19:528-530.
Nambu F., Yube N., Omawari N. (1991) Inhibition of endothelin-induced bronchoconstriction by OKY-046, a selective thromboxane A2 synthetase inhibitor, in guinea pigs. Adv. Prostaglandin Thromboxane Leukot. Res. 21:453-456.
Sakurai T., Yamaguchi S., Iwama T. (1994) Pharmacological studies of platelet-activating factor (PAF)-induced augmentation of response to histamine in guinea-pigs. Prostaglandins Leukot. Essent. Fatty Acids 51(2):95-99.
Saito M., Fujimura M., Sakamoto S. (1992) Involvement of arachidonate cyclooxygenase products in bronchial hyperresponsiveness induced by subthreshold concentration of aerosolized thromboxane A2 analogue (STA2) in guinea pigs. Allergy 47(2 PART 2):181-184.
Chung K.F., Aizawa H., Becker A.B. (1986) Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane synthetase inhibitor (OKY-046) in allergic dogs. Am. Rev. Respir. Dis. 134(2):258-261.
Komatsu H., Takehana Y., Kikuchi S. (1990) Effect of a thromboxane A2 synthetase inhibitor (OKY-046.HCI) on airway hyperresponsiveness in guinea pigs. Eur. J. Pharmacol. 184(1):87-95.
Sato T., Iwama T., Shikada K. (1996) Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs. Clin. Exp. Allergy 26(8):957-963.
Fujimura M., Sakamoto S., Matsuda T. (1990) Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma. Chest 98(3):656-660.
Miyamoto T., Ito K., Makino S. (1990) Clinical efficacy of OKY-046 in bronchial asthma in a multicenter, double-blind study. Igaku No Ayumi 154:385-406.
Makino S., Miyamoto T., Takishima T. (1990) Utility of OKY-046, a selective thromboxane synthetase inhibitor, on adult bronchial asthma in a multicenter, comparative, double-blind clinical study with azelastine hydrochloride. J. Clin. Ther. Med. 6:2131-2166.
Seki H., Kuromaki K., Takeda S. (1999) Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens. Pregnancy 18(2):157-164.
Tokiyoshi K., Ohnishi T., Nii Y. (1991) Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg. Neurol. 36(2):112-118.
Suzuki S., Sano K., Handa H. (1989) Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: A randomized double-blind study. Neurol. Res. 11(2):79-88.
Itoh H., Yamatani K., Oshida N. (1998) Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery. No To Shinkei 50(2):147-155.
Ashida Y., Matsumoto T., Kuriki H. (1989) A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins 38(1):91-112.
Shiraishi M., Kato K., Terao S. (1989) Quinones. 4. Novel eicosanoid antagonists: Synthesis and pharmacological evaluation. J. Med. Chem. 32(9):2214-2221.
Fukumoto S., Shiraishi M., Terashita Z. (1992) Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives. J. Med. Chem. 35(12):2202-2209.
Kurokawa T., Matsumoto T., Ashida Y. (1994) Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414. Biol. Pharm. Bull. 17(3):383-385.
Terao S., Shiraishi M., Matsumoto T. (1999) Thromboxane A2 antagonist-discovery of seratrodast. Yakugaku Zasshi 119(5):377-390.
Matsumoto T., Ashida Y., Tsukuda R. (1994) Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig. J. Pharmacol. Exp. Ther. 269(3):1236-1244.
Imai T., Adachi M., Idaira K. (1991) The effect of a specific thromboxane A2 antagonist, AA-2414 on airway hyperresponsiveness induced by ozone exposure in dogs. Arerugi 40(1):28-36.
Matsumoto T., Ashida Y. (1993) Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane A2 receptor antagonist (AA-2414) in Ascaris suum-allergic dogs. Prostaglandins 46(4):301-318.
Hoshino M., Sim J., Shimizu K. (1999) Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma. J. Allergy Clin. Immunol. 103(6):1054-1061.
Tamaoki J., Kondo M., Nakata J. (2000) Effect of a thromboxane A2 antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma. Chest 118(1):73-79.
Muramatsu H., Kotajima R., Sato T. (2001) Correlation between the clinical effects of seratrodast and the level of 11-dehydro-TXB2 in urine/sputum in bronchial asthma patients. Arerugi 50(6):540-546.
Perzborn E., Seuter F., Fiedler V.B. (1989) Action of the novel selective thromboxane antagonist (3R)-3-(4 -fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid on vascular smooth muscle preparations. Arzneimittelforschung. 39(12):1522-1525.
Norel X., Labat C., Gardiner P. (1991) Prostanoid contractions in human isolated pulmonary muscle preparations: Inhibition by BAY u3405. Adv. Prostaglandin Thromboxane Leukot. Res. 21 A:473-476.
Norman P., Cuthbert N.J., Gardiner P.J. (1991) BAY u3405 is a potent and competitive antagonist of U46619, PGD2 and 9-alpha, 11-beta PGF2 alpha-induced contractions of airway smooth muscle. Ann. NY Acad. Sci. 629:396-398.
Norel X., Labat C., Gardiner P.J. (1991) Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations. Br. J. Pharmacol. 104(3):591-595.
Francis H.P., Greenham S.J., Patel U.P. (1991) BAY u3405 an antagonist of thromboxane A2- and prostaglandin D2-induced bronchoconstriction in the guinea-pig. Br. J. Pharmacol. 104(3):596-602.
McKenniff M.G., Norman P., Cuthbert N.J. (1991) BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro. Br. J. Pharmacol. 104(3):585-590.
Francis H.P., Morris T.G., Thompson A.M. (1991) The thromboxane receptor antagonist BAY u3405 reverses prostaglandin D2 (PGD2)-induced bronchoconstriction in the anaesthetised guinea pig. Ann. NY Acad. Sci. 629:399-401.
Iwamoto I., Umibe T., Nakajima H. (1995) Effect of a selective thromboxane A2 receptor antagonist BAY u3405 on antigen-, leukotriene C4- and leukotriene D4-induced bronchoconstriction in guinea pigs. Int. Arch. Allergy Immunol. 108(1):68-73.
Magnussen H., Boerger S., Templin K. (1992) Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 89(6):1119-1126.
Johnston S.L., Bardin P.G., Harrison J. (1992) The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations. Br. J. Clin. Pharmacol. 34(5):402-408.
Rajakulasingam K., Johnston S.L., Ducey J. (1996) Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma. J. Appl. Physiol. 80(6):1973-1977.
Aizawa H., Shigyo M., Nogami H. (1996) BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest 109(2):338-342.
Obase Y., Shimoda T., Matsuo N. (1998) Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. Chest 114(4):1028-1032.
Arakida Y., Suwa K., Ohga K. (1998) In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J. Pharmacol. Exp. Ther. 287(2):633-639.
Arakida Y., Ohga K., Kobayashi S. (1998) Binding of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors, to guinea pig lung membranes. Eur. J. Pharmacol. 362(2-3):229-233.
Arakida Y., Ohga K., Suwa K. (2000) Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyperresponsiveness in guinea pigs. Jpn. J. Pharmacol. 82(4):287-294.
Arakida Y., Ohga K., Suwa K. (2000) In vivo pharmacologic profile of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors. Jpn. J. Pharmacol. 83(1):63-72.
